newsfilter
← Latest News
GlobeNewswire·

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

  • YD Bio Limited and EG BioMed Co., Ltd. officially launched the EG Telehealth Platform on March 31, 2026.
  • The platform is now live and enables access across 44 U.S. states, Washington, D.C., & Guam via a nationwide network of licensed physicians.
  • The collaboration integrates YD Bio's digital health infrastructure with EG BioMed's CLIA/CAP-certified laboratory capabilities to create an ecosystem for patient access, physician oversight, & cancer testing.
  • The decentralized model supports scalable deployment of diagnostic services for pancreatic, colorectal, liver, gastrointestinal, & breast cancers without requiring physical infrastructure expansion.
  • Key platform features include a commercialization-ready infrastructure, a nationwide licensed physician network, an integrated clinical & diagnostic ecosystem, a scalable asset-light operating model, & multi-indication design.
  • Dr. Ethan Shen, CEO of YD Bio, stated the launch transitions the company from technology development to scalable deployment to support future partnerships & expanded diagnostic offerings.
  • YD Bio entered a Memorandum of Understanding to merge with EG BioMed in January 2026, with the transaction anticipated to close in 2026 pending regulatory approvals & final agreements.
  • YD Bio operates DNA methylation-based oncology testing programs in the U.S. under an LDT-first strategy & maintains ocular health commercialization operations in Asia.
  • The press release includes standard forward-looking statements regarding strategy, the merger, & future performance, warning that actual results may differ due to regulatory & other risks.